GRAIL Inc. (GRAL)
| Bid | 32.05 |
| Market Cap | 1.09B |
| Revenue (ttm) | 132.29M |
| Net Income (ttm) | -2.13B |
| EPS (ttm) | -63.54 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 33.11 |
| Volume | 1,193,592 |
| Avg. Volume (20D) | 1,450,560 |
| Open | 31.50 |
| Previous Close | 30.29 |
| Day's Range | 31.45 - 33.49 |
| 52-Week Range | 12.33 - 63.99 |
| Beta | 3.16 |
About GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...
Analyst Forecast
According to 2 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $20, which is a decrease of -37.68% from the latest price.
Stock Forecasts
2 months ago · investopedia.com
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 i...